Costs of long-course palliative radiotherapy acceptable in late-stage lung cancer

December 19, 2006

A longer, less intense course of radiotherapy provides better value for the money than a shorter, more intense regimen when given to ease pain and other complaints in patients with late-stage non-small-cell lung cancer (NSCLC), according to a study in the December 20 issue of the Journal of the National Cancer Institute.

Patients with late-stage NSCLC are often too ill to receive intensive treatment for their cancer. Palliative radiotherapy is given to ease symptoms such as chest pain and difficulty breathing and swallowing. In 1999, Wilbert B. van den Hout, Ph.D., of Leiden University Medical Center in the Netherlands, and colleagues conducted a randomized clinical trial in 297 patients with inoperable stage IIIA/B or stage IV NSCLC to compare two palliative radiotherapy regimens--a short course, two treatments of 8 gray (Gy) of radiation each, with a long course, 10 treatments of 3 Gy each. They found that the long course better eased symptoms over time and improved 1-year survival compared with the short course.

However, that study did not take into account the higher costs of the longer treatment and the continued medical costs of the patients who survive longer with their cancer. For this new study, van den Hout and colleagues conducted a cost-utility analysis of the two treatments to see which offers the best value for the money. Using data from a patient questionnaire on factors such as their mobility, ability to perform usual activities, and pain and anxiety levels, the authors calculated that quality of life was roughly equal in both treatment groups. However, because life expectancy was longer in the long-course treatment group, that group's overall quality-of-life benefit was greater than that in the short-course group.

The researchers also estimated the costs associated with the treatment and other nontreatment costs, such as medical care for people who survived their cancer. They estimated that the lifetime societal costs of the long-course radiotherapy were $16,490 and the short-course radiotherapy costs were $11,164, a $5,326 difference. In their final calculations, the authors found that, although the dollar costs of the long-course radiotherapy were higher than those of the short course, the benefit in improved survival meant that the long-course treatment yielded benefit at an acceptable cost by current economic standards.

"In our group of poor-prognosis non-small-cell lung cancer patients, the additional costs of the protracted radiotherapy schedule were justified by longer survival rather than by improved quality of life," the authors conclude.

The authors point out that their study does not show that long-course radiotherapy reduces costs. In addition, areas with limited radiotherapy facilities may find it more efficient to treat patients with the shorter course. Finally, different countries and regions may have different economic factors that influence the decision of which radiotherapy regimen to use.
-end-
EMBARGOED FOR RELEASE: 19 DECEMBER 2006 16:00 EST

Contact:

• Leiden University Medical Center Communications Department, telephone: +31 (71) 526 8005, e-mail: communicatie@lumc.nl

Citation:

• van den Hout WB, Kramer GWPM, Noordijk EM, Leer JWH. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst 2006; 98:1786-94.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.